Partners for 2020
Partners Confirmed For 2020
We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC-induced protein degradation: compound binding and permeability, ternary complex formation, ubiquitination, and trafficking to proteasome. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.
NJ Bio is a quality CRO that provides integrated chemistry and biology services. Main service areas include multistep organic synthesis, medicinal chemistry, bioconjugation, antibody-drug conjugates as well as flow and high-pressure chemistry, which is provided in alliance with Amar Chemistry Pvt. Ltd. in Mumbai.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Founded in 1990, Schrödinger has nearly 400 employees and operations across the world.
Chemical Computing Group
CCG (Chemical Computing Group) is a leading supplier of software solutions for life sciences. With a proven track record in scientific innovation, CCG provides state-of-the-art applications in drug discovery to pharmaceutical, biotechnology and academic researchers. CCG headquarters are in Montreal (Canada), with support offices in North America, Europe and Asia.
LifeSensors generates reagents and drug discovery platforms which enable researchers to accurately and effectively assay the Ubiquitin Proteasome System. In addition to off-the-shelf products and kits, LifeSensors also partners with companies and researchers around the world to develop novel drug discovery assays. LifeSensors’ powerful technologies in conjunction with our expertise in the UPS, have enabled researchers to target and assay the undruggable targets.
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule targets Acute Myeloid Leukemia (in clinic Q2 2019) and our lead Protein Homeostatic Modulator (PHM™) will be in the clinic Q3 2020 for hematological malignancies.
Bio-Techne brings together some of the most referenced brands in life science to provide innovative tools for Targeted Protein Degradation. Boston Biochem are world leaders in ubiquitin-proteasome system-related products, Tocris Bioscience are market leaders for research tool Degraders and Degrader building blocks while ProteinSimple provide automated platforms for detecting and quantifying protein degradation via Western Blot.
Together we are Bio-Techne. Find out how we can help you achieve your research goals.
At MilliporeSigma, our purpose is to solve the toughest problems in life science. To accelerate discovery for Targeted Protein Degradation, our Sigma-Aldrich Chemical Biology portfolio simplifies synthesis and library generation of protein degraders with degrader building blocks and custom synthesis capabilities. In addition to new degrader probes and lead discovery tools, TPD research is supported through our extensive offerings in bioactive small molecules, antibodies, western blotting, and genome editing tools such as CRISPR.
Aurelia Bioscience is a UK based pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner. They work in early stages of the drug discovery pipeline including target identification and validation, hit identification, hit to lead as well as lead identification and optimisation.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
FIDA technology quantifies and characterizes protein behaviour in complex samples including plasma, serum and fermentation media. The read-out is an absolute measure of protein/complex size in nanometers. The absolute read-out enables Determination of ternary complex size, Assessment of multiple Kd’s in formation of complex and Identification of fraction bound. It is possible to work with molecules and particles ranging 0,5-1000 nm. The technology is characterized by rapid assay development, minimal sample preparation, nanolitre sample consumption.
Syngene International Ltd
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation-focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene’s clientele includes world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4240-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed up time to market and lower the cost of innovation.